Nanjing King-Friend Biochemical Pharmaceutical (603707.SS) Earnings Analysis
Nanjing King-Friend Biochemical Pharmaceutical (603707.SS) next reports earnings on 2026-08-29, consensus EPS 0.15 CNY. Last quarter (2026-04-30) it missed with EPS 0.1 CNY vs 0.26 CNY est (-61.5%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E 21.39.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 603707.SS next report earnings?
| Next earnings date | 2026-08-29 |
|---|---|
| Consensus EPS estimate | 0.15 CNY |
| Revenue estimate | 0.93B |
603707.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | 0.1 CNY | 0.26 CNY | -61.5% | Miss |
| 2025-09-29 | 0.08863 CNY | 0.24 CNY | -63.1% | Miss |
| 2025-06-30 | 0.1276 CNY | 0.13 CNY | -1.8% | Miss |
| 2025-04-28 | 0.13 CNY | 0.13 CNY | 0% | Beat |
| 2024-12-31 | 0.1317 CNY | n/a | n/a | n/a |
| 2024-08-30 | 0.141 CNY | n/a | n/a | n/a |
Beat rate: 1/4 (25%) over reported quarters with consensus data.
603707.SS valuation and analyst view
| Trailing P/E | 21.39 |
|---|---|
| Trailing EPS | 0.36291 CNY |
| Price / book | 1.82 |
| Dividend yield | 1.27% |
| Market cap | 12.72B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Nanjing King-Friend Biochemical Pharmaceutical (603707.SS)'s next earnings date?
Nanjing King-Friend Biochemical Pharmaceutical is next scheduled to report on 2026-08-29, with a consensus EPS estimate of 0.15 CNY and revenue estimate of 0.93B.
Did 603707.SS beat earnings last quarter?
In its 2026-04-30 report, 603707.SS posted EPS of 0.1 CNY versus a 0.26 CNY estimate — a miss of 61.5%.
What is 603707.SS's earnings track record?
Over the last 4 reported quarters with consensus data, 603707.SS beat estimates 1 times (25%).
What is 603707.SS's current P/E ratio and EPS?
603707.SS trades at a trailing P/E of 21.39 on trailing EPS of 0.36291103290051757 CNY.
What do analysts rate 603707.SS?
603707.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.